Onesource Specialty Pharma Credit Rating Upgraded to IND A

Onesource Specialty Pharma Ltd's bank loan facilities have been upgraded by India Ratings and Research (Ind-Ra) to 'IND A' with a Positive outlook. The short-term rating is 'IND A1'. The upgrade covers total bank facilities of INR 11,250.51 million and assigns ratings to an additional INR 4,287.08 million.

Reader Takeaway: Positive rating upgrade; contingent liabilities and rising leverage are key risks.

What just happened

India Ratings has upgraded Onesource Specialty Pharma's long-term credit rating to 'IND A' with a Positive outlook, from a previous unspecified level. The short-term rating remains 'IND A1'.

Why this matters

The upgrade signals improved creditworthiness and can potentially lower borrowing costs for the company. It validates the company's strategic shift towards commercial supply-led revenue streams, which is crucial for investor confidence.

The backstory

Ind-Ra’s rationale for the upgrade is the company's successful commercialization of its drug-device combination (DDC) platform and increased contributions from glucagon-like peptide-1 (GLP-1) supplies. This marks a transition from a development-focused model to one driven by commercial sales, supported by customer launches and long-term supply agreements.

What changes now

With the 'IND A' rating and a Positive outlook, Onesource Specialty Pharma is perceived as having a stronger business profile and improving credit metrics. Ind-Ra expects these trends to continue, driven by GLP-1 opportunities and commercial supply agreements.

Risks to watch

Key risks highlighted include contingent liabilities of INR 12,862 million from arbitration over Sputnik Light Vaccine supply, increased gross debt to INR 15,200 million in FY26, and a rise in net leverage to 4.7x in FY26 from 1.6x in FY25. The company also faces high working capital intensity (194 days) and risks related to its export-heavy revenue (71% in FY26) and currency fluctuations.

Peer comparison

While specific peer data isn't provided, the shift to a commercial supply-led model and increasing GLP-1 contributions are industry trends in the specialty pharma sector, aiming for higher margins and stable revenues.

Context metrics (time-bound)

For FY26, revenue was INR 14,216 million, with EBITDAR at INR 3,042 million and an EBITDAR margin of 21.4%. Net leverage stood at 4.7x. For FY25, revenue was INR 14,449 million, EBITDAR was INR 4,665 million, EBITDAR margin was 32.3%, and net leverage was 1.6x.

What to track next

Investors should monitor the resolution of the Sputnik Light vaccine arbitration, the company's ability to manage its rising leverage, and improvements in working capital efficiency. The expected decline in debt from FY28, as commercialization ramps up, will be a key indicator.